Atea Pharmaceuticals (AVIR) Capital Expenditures (2020 - 2022)
Atea Pharmaceuticals (AVIR) posted quarterly Capital Expenditures of $20000.0 for Q3 2022, down 98.94% quarter-over-quarter from $1.9 million in Q2 2022.
Powered by 
Analysis
Atea Pharmaceuticals (AVIR) Capital Expenditures (2020 - 2022) Analysis & Trends
Atea Pharmaceuticals' Capital Expenditures history runs 2 years deep, the most recent figure standing at $20000.0 for Q3 2022.
- In Q3 2022, Capital Expenditures changed N/A year-over-year to $20000.0; the TTM figure through Dec 2022 stood at $1.9 million (changed N/A YoY), while the FY2022 annual figure was $1.9 million, up 48475.0% from the prior year.
- Capital Expenditures for Q3 2022 stood at $20000.0, down from $1.9 million in the prior quarter.
- The five-year high for Capital Expenditures was $1.9 million in Q2 2022, with the low at $5000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Atea Pharmaceuticals | 467.50 Mn | 467.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 20,000.00 |
| Jun 30, 2022 | 1.22 Mn |
| Mar 31, 2022 | 702,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Sep 30, 2020 | 15,000.00 |